Vertex Pharmaceuticals, Inc.

The General Hospital Corporation

Boston University

Samuel Moskowitz

Weichao George Chen

Sarah Robertson

Eric L Haseltine

David Waltz

Eleni Dokou

Varsha Dhamankar

Beili Zhang

Lori Ann Ferris

Kirk Raymond Dinehart

Katie McCarty

Nishanth Gopinathan

Catherine Metzler

James Joseph Collins

Sylvain Meylan

Cathy Chu

Katie Mccarty

Welchao George Chen

Compound I of the formula and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

Methods of treatment for cystic fibrosis

Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis. 

Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and treatment with one or more proton motive force (PMF) stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known.

Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections

Compound I of the formula (formula) A pharmaceutically acceptable salt of Compound I. Pharmaceutical compositions containing at least Compound I and methods of treating cystic fibrosis comprising administering at least Compound I. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound I. 

A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.

Pharmaceutical compositions for treating cystic fibrosis

Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Crystalline forms and compositions of CFTR modulators

Growing community of inventors

Waban, MA, United States of America

Samuel Moskowitz